Abstract | BACKGROUND: METHODS: Patients initially negative for hepatitis B (HB) surface antigen ( HBsAg), and with core antibody (anti-HBc) and nonprotective anti-HBs titers (<100 mIU/mL) were selected. Four doses of 40 microng of either vaccine were administered intramuscularly, further doses being given 1, 2 and 6 months after the first dose. Seroconversion and seroprotection were defined as anti-HBs level above 10 mIU/mL and 100 mIU/mL, respectively. RESULTS: A total of 11 and 9 subjects receiving GeneVac-B and Engerix-B, respectively, completed the protocol. Seroconversion was achieved in 100% for both vaccines. Seroprotection occurred in 78% and 82% of the Engerix-B and the GeneVac-B recipients, respectively. Geometric mean titers 1 month after the fourth dose were 274 mIU/mL (95% confidence interval [95% CI], 71-1,057 mIU/mL) and 322 mIU/mL (95% CI, 142-730 mIU/mL), respectively. CONCLUSIONS: Both vaccines are highly immunogenic in renal failure and did not show significant differences between each other.
|
Authors | Mohan M Rajapurkar, Sishir Gang, Manish Dabhi, Prasad S Kulkarni |
Journal | Journal of nephrology
(J Nephrol)
2007 Sep-Oct
Vol. 20
Issue 5
Pg. 596-601
ISSN: 1121-8428 [Print] Italy |
PMID | 17918146
(Publication Type: Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Engerix-B
- GeneVac B
- Hepatitis B Antibodies
- Hepatitis B Vaccines
- Vaccines, Synthetic
|
Topics |
- Adult
- Female
- Hepatitis B
(immunology, prevention & control)
- Hepatitis B Antibodies
(blood)
- Hepatitis B Vaccines
(administration & dosage, adverse effects, immunology, therapeutic use)
- Humans
- Immunization Schedule
- Injections, Intramuscular
- Kidney Failure, Chronic
(immunology, therapy)
- Male
- Middle Aged
- Renal Dialysis
- Vaccines, Synthetic
(immunology)
|